Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 8-week, multicenter, open-label, observational study of the efficacy of quetiapine fumarate [quetiapine] (Seroquel) immediate-release tablets in adult patients with bipolar depression

Next Previous
Trial Profile

A 8-week, multicenter, open-label, observational study of the efficacy of quetiapine fumarate [quetiapine] (Seroquel) immediate-release tablets in adult patients with bipolar depression

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2008

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Bipolar disorders
  • Focus Therapeutic Use
  • Acronyms QUEEN
  • Sponsors AstraZeneca

Most Recent Events

  • 01 Mar 2025 Results (n=232) administration of PHEN/TPM CR plus lifestyle intervention in Korean adults with obesity resulting in a greater reduction in body weight and adiposity than lifestyle intervention alone, were published in the Diabetes, Obesity and Metabolism
  • 05 Oct 2008 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
  • 05 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top